Literature DB >> 30557454

The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.

Charlotte Starhof1, Anne-Mette Hejl1, Niels H H Heegaard2,3, Anting L Carlsen2, Mark Burton4, Berit Lilje5, Kristian Winge1,6.   

Abstract

BACKGROUND: MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids.
OBJECTIVES: The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways.
METHODS: In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex.
RESULTS: A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF.
CONCLUSIONS: Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  CSF; Parkinson's disease; biomarker; microRNA; multiple system atrophy

Year:  2018        PMID: 30557454     DOI: 10.1002/mds.27542

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

1.  Plasma miR-153 and miR-223 Levels as Potential Biomarkers in Parkinson's Disease.

Authors:  Li Wu; Qian Xu; Mengxi Zhou; Yajing Chen; Chunyan Jiang; Yuhan Jiang; Yin Lin; Qing He; Lei Zhao; Yourong Dong; Jianren Liu; Wei Chen
Journal:  Front Neurosci       Date:  2022-05-17       Impact factor: 5.152

Review 2.  Clinical Application of Circulating MicroRNAs in Parkinson's Disease: The Challenges and Opportunities as Diagnostic Biomarker.

Authors:  Palaniswamy Ramaswamy; Ravi Yadav; Pramod Kumar Pal; Rita Christopher
Journal:  Ann Indian Acad Neurol       Date:  2020-01-21       Impact factor: 1.383

Review 3.  MicroRNAs Dysregulation and Metabolism in Multiple System Atrophy.

Authors:  Chunchen Xiang; Shunchang Han; Jianfei Nao; Shuyan Cong
Journal:  Front Neurosci       Date:  2019-10-17       Impact factor: 4.677

4.  MicroRNA expression in the cerebrospinal fluid of dogs with and without cervical spondylomyelopathy.

Authors:  Daniella P Vansteenkiste; Joelle M Fenger; Paolo Fadda; Paula Martin-Vaquero; Ronaldo C da Costa
Journal:  J Vet Intern Med       Date:  2019-10-22       Impact factor: 3.333

Review 5.  The Study of Cerebrospinal Fluid microRNAs in Spinal Cord Injury and Neurodegenerative Diseases: Methodological Problems and Possible Solutions.

Authors:  Irina Baichurina; Victor Valiullin; Victoria James; Albert Rizvanov; Yana Mukhamedshina
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

6.  Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease.

Authors:  Lucas Caldi Gomes; Ana Galhoz; Gaurav Jain; Anna-Elisa Roser; Fabian Maass; Eleonora Carboni; Elisabeth Barski; Christof Lenz; Katja Lohmann; Christine Klein; Mathias Bähr; André Fischer; Michael P Menden; Paul Lingor
Journal:  Clin Transl Med       Date:  2022-01

Review 7.  Targeting microRNAs to Regulate the Integrity of the Blood-Brain Barrier.

Authors:  Juntao Wang; Fang Xu; Xiaoming Zhu; Xianghua Li; Yankun Li; Jia Li
Journal:  Front Bioeng Biotechnol       Date:  2021-06-11

Review 8.  Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.

Authors:  Oxana P Trifonova; Dmitri L Maslov; Elena E Balashova; Guzel R Urazgildeeva; Denis A Abaimov; Ekaterina Yu Fedotova; Vsevolod V Poleschuk; Sergey N Illarioshkin; Petr G Lokhov
Journal:  Diagnostics (Basel)       Date:  2020-05-25

Review 9.  The Functional Role of microRNAs in the Pathogenesis of Tauopathy.

Authors:  Domenico Praticò
Journal:  Cells       Date:  2020-10-09       Impact factor: 6.600

Review 10.  Technical and Methodological Aspects of Cell-Free Nucleic Acids Analyzes.

Authors:  Zuzana Pös; Ondrej Pös; Jakub Styk; Angelika Mocova; Lucia Strieskova; Jaroslav Budis; Ludevit Kadasi; Jan Radvanszky; Tomas Szemes
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.